Plasma F2 isoprostanes: Direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes

Diabetes Care

Volumn 25, Issue 3, 2002, Pages 537-541

  Sampson, Michael J ^a   Gopaul, Nitin ^b   Davies, Isabel R ^c   Hughes, David A ^c   Carrier, Martin J ^b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c INSTITUTE OF FOOD RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FREE RADICAL; GLUTATHIONE; ISOPROSTANE DERIVATIVE; MEMBRANE PHOSPHOLIPID; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; CHOLESTEROL; DRUG DERIVATIVE; GLUTATHIONE DISULFIDE; PROSTAGLANDIN F2 ALPHA;

ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; GAS CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; LYMPHOCYTE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OXIDATION; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE; ADULT; AGED; BLOOD; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIOXIDANTS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DINOPROST; F2-ISOPROSTANES; FEMALE; FREE RADICALS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCOSE TOLERANCE TEST; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUMANS; HYPERGLYCEMIA; LYMPHOCYTES; MALE; MIDDLE AGED;

EID: 0036511430     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.3.537     Document Type: Article

References (35)

1. Hanefeld M, Julius U, Schmechel H, Schwanebeck U: Postprandial hyperglycemia is a risk factor for cardiovascular death in newly diagnosed type 2 diabetes: the Diabetes Intervention Study (DIS) (Abstract). Atherosclerosis 151 (Suppl. 1):1, 2000
2. Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycemic threshold for mortality risk? Diabetes Care 22:696-699, 1999
3. Balkau B, Eschwege E, Papoz L, Richard J-L, Claude J-R, Warnet J-M: Risk factors for early death in NIDDM and men with known glucose tolerance status. Br Med J 307:295-299, 1993
4. Lefebvre PJ, Scheen AJ: The postprandial state and risk of cardiovascular disease. Diabet Med 15 (Suppl. 4):S63-S68, 1998
5. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications (Review). Diabetes Care 3:257-267, 1996
6. Delmas-Beauvieux MC, Peuchant E, Thomas MJ: The place of electron spin resonance methods in the detection of oxidative stress in type 2 diabetes with poor glycemic control. Clin Biochem 31:221-228, 1998
7. Halliwell B, Gutteridge JMC: Role of free radicals and catalytic metal ions in human disease an overview (Review). Methods Enzymol 186:1-85, 1990
8. Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, Zacken WE, Awad JA, Roberts LJ: The isoprostanes: unique prostaglandin like products of free radical initiate lipid peroxidation. Drug Metab Rev 31:117-139, 1999
9. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ 2nd: Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med 332:1198-1203, 1995
10. Barden A, Beilin LJ, Ritchie J, Croft KD, Walters BN, Michael CA: Plasma and urinary 8 isoprostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy. Clin Sci 91:711-718, 1996
11. PGF 2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 225-229, 1995
12. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C: In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224-229, 1999
13. Nemeth I, Boda D: The ratio of oxidised: reduced glutathione as an index of oxidative stress in various experimental models of shock syndrome. Biomed Biochim Acta 48:553-557, 1989
14. Baker MA, Cerniglia GJ, Zaman A: Microtiter palate assay for the measurement of glutathione: and glutathione disulfide in large numbers of biological samples. Anal Biochem 190:360-365, 1990
15. Nourooz-Zadeh J, Gopaul NK, Barrow S, Mallet AI, Anggard EE: Analysis Of F2-isoprostanes as indicators of nonezymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure. J Chromatogr B Biomed Appl 667:199-208, 1995
16. 2-isoprostane levels. Free Rad Biol Med 28:806-814, 2000
17. Friedewald WT, Levy RI, Frederikson DS: Estimation of the concentration of LDL cholesterol: in plasma without the use of the preparative centrifuge. Clin Chem 18:499-502, 1972
18. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A: Meal generated oxidative stress in type 2 diabetic patients. Diabetes Care 21:1529-1533, 1998
19. Ceriello A, Bortolotti N, Crescentini A: Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 28:329-333, 1998
20. Konukoglu D, Hatemi H, Ozer EM, Gonen S, Akcay T: The erythrocyte glutathione levels during oral glucose tolerance test. J Endocrinol Invest 20:471-475, 1998
21. Tessier D, Khalil A, Fulop T: Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. Gerontol A Biol Sci Med Sci 54:M541-M545, 1999
22. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C: Meal induced oxidative stress and low density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 48:1503-1508, 1999
23. Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR: Postprandial low density lipoproteins in type 2 diabetes are oxidised more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 222:178-184, 1999
24. Staprans I, Hardman DA, Pan XM, Feingold KR: Effect of oxidised lipids in the diet on oxidised lipid levels in postprandial serum chylomicrons of diabetic patients. Diabetes Care 22:300-306, 1999
25. Gopaul NK, Halliwell B, Anggard EE: Measurement f plasma F2-isoprostanes as an index f lipid peroxidation does not appear to be confounded by diet. Free Radic Res 33:115-127, 2000
26. Laight DW, Carrier MJ, Anggard EE: Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev 15:274-282, 1999
27. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montera A: Free radical generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int 56:471-478, 1999
28. Minuz P, Andrioli G, Degan M, Gaino S, Ortolani R, Tommasoli R, Zuliani V, Lechi A, Lechi C: The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 18:1248-1256, 1998
29. Gniwotta C, Morrow JD, Roberts LJ, Kuhn H: Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 17:3236-3241, 1997
30. PGF 2alpha in human atherosclerotic vascular tissue. Prostaglandins Leukot Essent Fatty Acids 60:129-134, 1999
31. Groeneveld Y, Petri H, Hermans J, Springer MP: Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 16:12-13, 1999
32. 1c level. Diabetes Care 23:1830-1834, 2000
33. DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1994
34. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 92:1866-1874, 1993
35. Galis ZS, Asanuma K, Godin D, Meng X: N-acetyl-cysteine: decreases the matrix degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 97:2445-2453, 1998